Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Chronic stable angina,Vasospastic angina (Prinzmetal's angina),Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
92-98% bound to serum albumin.
92-98% bound primarily to albumin.
1.0-1.5 L/kg; large distribution suggests extensive tissue penetration.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Immediate-release: 40-60% (extensive first-pass metabolism); sustained-release: 80-90% relative to immediate-release formulation.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No specific dose adjustment required; use caution in severe renal impairment (GFR <30 m L/min).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Child-Pugh Class A: reduce dose by 50%; Class B or C: contraindicated or use with extreme caution, reduce dose by 60-75%.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not FDA-approved for pediatric use; off-label: 0.25-0.5 mg/kg/dose orally every 6-8 hours, maximum 3 mg/kg/day.
Safety and efficacy not established; use is not recommended in pediatric patients.
Initiate at lower doses (e.g., 10 mg immediate-release 3 times daily or 30 mg XL once daily); titrate slowly; monitor for hypotension and edema.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
No FDA-issued black box warning.
No FDA black box warning.
May cause severe hypotension especially with concomitant beta-blockers,Peripheral edema,Gingival hyperplasia,Hepatic impairment may require dose adjustment,Avoid abrupt discontinuation (may worsen angina),Increased risk of myocardial infarction in patients with coronary artery disease
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Acute myocardial infarction (within first 4 weeks),Concomitant use with strong CYP3A4 inducers or inhibitors
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Grapefruit juice and grapefruit increase the AUC and Cmax of nifedipine by approximately 2-fold due to CYP3A4 inhibition; avoid concurrent consumption. Alcohol may exacerbate hypotension and vasodilatory effects. High-fat meals can delay absorption of extended-release tablets but do not significantly alter overall bioavailability.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second and third trimesters: Associated with reduced uteroplacental blood flow, fetal hypoxia, and low birth weight. Tocolysis use may cause maternal hypotension and fetal distress. Overall, FDA Category C.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Nifedipine is excreted into breast milk; milk-to-plasma ratio approximately 1.0. Low relative infant dose (2-5% of maternal weight-adjusted dose). No reported adverse effects in breastfed infants. However, caution is advised, especially in preterm or low-birth-weight infants. Monitor infant for hypotension or adverse effects.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No standard dose adjustment required. However, increased clearance and volume of distribution in pregnancy may require dose titration to achieve clinical effect. Start with lowest effective dose.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
Nifedipine (Procardia) is a dihydropyridine calcium channel blocker with potent vasodilatory effects. Avoid sublingual administration of short-acting capsules due to risk of profound hypotension, myocardial ischemia, and stroke. Use only extended-release formulations for chronic hypertension or stable angina. May cause peripheral edema; differentiate from heart failure. Gingival hyperplasia can occur with chronic use. Contraindicated in patients with a history of hypersensitivity to dihydropyridines, cardiogenic shock, significant aortic stenosis, or within 4 weeks of myocardial infarction.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit juice and grapefruit products as they increase nifedipine levels and risk of toxicity.,Report persistent swelling of ankles/feet, severe headaches, dizziness, or palpitations to your healthcare provider.,Rise slowly from sitting or lying positions to minimize orthostatic hypotension.,Practice good oral hygiene and regular dental check-ups to reduce risk of gum overgrowth.,Do not stop taking this medication abruptly; taper under medical supervision to avoid rebound angina.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA vs ADALAT CC, answered by our medical review team.
PROCARDIA is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA is: Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA is classified as Category C. First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second an. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.